Brain Cancer SPORE Grant
Originally awarded: October 2004 ($10.8 million over five years)
Award renewal: September 2011 ($11.4 million over five years)
Principal investigator: Brian Patrick O'Neill, M.D.
Co-principal investigator: Robert B. Jenkins, M.D., Ph.D.
The Mayo Clinic Cancer Center is 1 of only 4 U.S. cancer centers to receive a National Cancer Institute-sponsored Specialized Program of Research Excellence (SPORE) grant for brain cancer research.
The Mayo Clinic Brain Cancer SPORE Grant promotes a strong collaboration between basic research scientists and clinicians in order to foster meaningful translational studies about brain cancer.
Researchers in the Mayo Clinic Brain Cancer SPORE study the pathogenetic mechanisms that can lead to the development of brain cancer, especially gliomas.
Researchers in the Brain Cancer SPORE also develop interventions that can help improve the length and quality of life for patients with brain cancer.
The Mayo Clinic Brain Cancer SPORE focuses on several priorities that were developed by the national Brain Tumor Progress Review Group, including:
- Facilitating the development of novel and less toxic therapeutic agents to treat brain cancer
- Gaining a better understanding of the mechanisms of current agents and therapies and improving treatment outcomes
- Developing teams of like-minded scientists and clinicians (clinical consortia) for immunotherapy
For more information about the Mayo Clinic Brain Cancer SPORE, see: